June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Restoration of M-cone function in an S-cone only mouse model of human blue cone monochromacy by AAV-mediated expression of human L- or M-opsin
Author Affiliations & Notes
  • Ji-Jing Pang
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Wentao Deng
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Yuxin Zhang
    Ophthalmology, University of Florida, Gainesville, Florida, United States
    Ophthalmology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China
  • Jie Li
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Ping Zhu
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Wolfgang Baehr
    Ophthalmology, University of Utah, Salt Lake City, Utah, United States
  • William W Hauswirth
    Ophthalmology, University of Florida, Gainesville, Florida, United States
  • Footnotes
    Commercial Relationships   Ji-Jing Pang, None; Wentao Deng, None; Yuxin Zhang, None; Jie Li, None; Ping Zhu, None; Wolfgang Baehr, None; William Hauswirth, AGTC (F), AGTC (C), AGTC (P)
  • Footnotes
    Support  NIH grant EY021721, EY023543, BCM Families Foundation, AGTC, MVRF, and RPB, Inc.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4478. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ji-Jing Pang, Wentao Deng, Yuxin Zhang, Jie Li, Ping Zhu, Wolfgang Baehr, William W Hauswirth; Restoration of M-cone function in an S-cone only mouse model of human blue cone monochromacy by AAV-mediated expression of human L- or M-opsin. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4478.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Blue cone monochromacy (BCM) is an X-linked congenital disorder with severe cone dysfunction due to the absence of the long and medium wavelength-sensitive cone function. In this study, we used an M-opsin knockout (Opn1mw-/-) mice with only S-cone function remaining as a model to test gene therapy for BCM by AAV-mediated delivery of either human M- or L-opsin, homologues of the mouse M-opsin.

Methods : We generated AAV5 vectors expressing either human L-opsin or human M-opsin driven by the cone-specific PR2.1 promoter. 1 microliter (5 × 1012 vector genomes/mL) of each vector was injected subretinally into one eye of one month old Opn1mw-/- mice, while the contralateral eyes remain untreated and served as controls. M-cone mediated retinal function was analyzed by full-field photopic ERG under middle wavelength flash conditions (510nm). Human L- and M-opsin transgene expression and their cellular localization were examined by immunohistochemistry using anti-L/M-opsin, anti-S-opsin antibodies and peanut agglutinin (PNA). The levels of transgene expression were assessed by Western blot analysis.

Results : Untreated Opn1mw-/- mice have no M-cone function and only S-cone function primarily in their ventral retina. Treatment with either human M- or L-opsin rescued middle wavelength ERG responses to about 60% of normal b-wave amplitudes. AAV delivered human M-opsin or L-opsin was detected panretinally. In dorsal retinas, M-opsin or L-opsin was localized within PNA-labeled cone sheaths in cone outer segments. In ventral retinas where S-cones are present, M-opsin or L-opsin was co-localized with endogenous mouse S-opsin in cone outer segments. Western blot analysis showed that AAV-delivered M- or L-opsin was about 65% of the wildtype level which is consistent with the level of ERG rescue.

Conclusions : We demonstrate that AAV-mediated expression of either human M-opsin or L-opsin can restore ERG responses to middle wavelength light in Opn1mw-/- mice. Vectored human opsins were expressed in cone outer segments in both dorsal and ventral retinas. These results also demonstrate that cones with one type of opsin, endogenous S-opsin in this case, can co-exist with a second type of vector delivered opsin, human L-opsin or M-opsin without physiological effects. These observations provide proof-of-concept for eventually treating BCM patients by gene therapy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×